Table 2.

Tofacitinib pharmacokinetic parameters in plasma following IV and PO administration.

Route	Sex	Dose	C0/Cmax	Tmax	AUC(0-24)	AUC(0-inf)	t½	CL/CL_F	Vss/Vz_F	%F
Unit		mg/kg	ng/mL	h	h*ng/mL	h*ng/mL	h	mL/h/kg	mL/kg	%
IV	M	10	3554.4	N/A	676.76	678.09	1.85	14747.23	39278.78	N/A
PO	M	20	960	0.25	505.74	508.48	0.91	39332.99	51817.31	37.4
IV	F	10	6516.9	N/A	980.54	982.90	0.72	10173.94	10549.83	NA
PO	F	20	1114.3	0.167	713.26	719.57	0.90	27794.47	36093.12	36.4

IV, intravenous, PO, per os; C0, concentration at time 0; Cmax, maximum observed concentration; Tmax, time to reach Cmax; AUC_(0-24), area under the concentration-time curve from time zero to 24 hours; AUC_(0-inf), area under the concentration-time curve from time zero to infinite; CL, systemic clearance; CL_F, apparent clearance; Vss, volume of distribution at steady state; Vz_F, volume of distribution associated with the terminal elimination phrase; terminal elimination half-life (t½) was calculated based on data points (≥3) in the terminal phase with correlation of coefficient >0.90; %F, bioavailability; N/A, not applicable.